Robots as a Tool for Reducing Contamination in Pharmaceutical Facilities

 Image by Tim Sandle.

Robotics is becoming increasingly important in pharmaceutical contamination control, particularly where manufacturing or testing requires very low levels of microbial and particulate contamination. The central advantage is straightforward: robots can remove or reduce the human operator from critical activities. This is significant because personnel are one of the principal sources of microorganisms, particles and fibres within cleanrooms. Internal guidance on advanced robotics similarly identifies reduced human intervention in aseptic manufacture as an important means of lowering contamination risk.

This principle fits particularly well with modern Contamination Control Strategy (CCS) thinking. Rather than relying primarily upon environmental monitoring to detect contamination after it has occurred, facilities should seek to prevent contamination through appropriate engineering and process design. Isolators already contribute to this by providing a physical separation between the operator and critical processing environment. More advanced isolators go further, replacing glove-port manipulations with robotics.

Robotic environmental monitoring

One particularly useful application is the robotic handling of environmental monitoring media within an isolator. Conventionally, placing, exposing, retrieving and manipulating settle plates or other microbiological monitoring devices may require glove manipulations. Every such manipulation introduces some risk through glove contact, disturbance of airflow or accidental interference with critical surfaces.

A robotic system can instead manipulate Petri dishes in a predefined and repeatable manner. For example, a robot could position a settle plate at a defined monitoring location, remove or replace its lid as required by the validated monitoring procedure, and subsequently retrieve the plate for transfer from the isolator. The important contamination-control benefit is not that the robot is intrinsically sterile, but that the operation becomes repeatable and less dependent upon human intervention.

This is particularly attractive in gloveless isolators, where the objective is to eliminate operator intervention in the critical zone. Internal material on modern aseptic filling describes closed, automated isolators without human intervention and specifically identifies robotic systems as technologies that can increase protection from extraneous contamination sources.

Robotics can similarly be applied to vial and syringe handling, component transfer, filling, stoppering, sampling and inspection. The technology therefore supports an important principle of aseptic processing: where an intervention can reasonably be eliminated through engineering, elimination is preferable to attempting repeatedly to control the same manual intervention.

Robots beyond the isolator

Robotics can also help contamination control at room level. Autonomous mobile robots, for example, can undertake selected cleaning or disinfection activities. One technology considered internally is autonomous UV-C disinfection. The information describes robots capable of mapping their environment and performing repeatable UV-C cycles with electronic recording of parameters such as exposure time and distance.

Such systems can reduce the amount of routine manual activity within controlled environments. However, they should be viewed as part of the CCS rather than as replacements for fundamental controls such as appropriate facility design, validated cleaning and disinfection, air filtration, material transfer controls and environmental monitoring.

Qualification and contamination-control considerations

Introducing robots does not automatically remove contamination risk. It changes the nature of the risk. Robotic equipment itself requires suitable hygienic design, cleanroom-compatible materials and surfaces that can be effectively cleaned or decontaminated. Equipment movement must not disrupt critical airflow, generate unacceptable particles or create difficult-to-clean areas.

For aseptic applications, the robotic operation also needs appropriate qualification and validation. Particular attention should be given to:

• reproducibility of movements and positioning;
• impact on first-air protection and airflow patterns;
• cleaning and biodecontamination compatibility;
• particle generation and lubricant containment;
• recovery from robot faults or dropped components;
• interventions required following mechanical failure;
• data integrity and software control; and
• integration into APS/media-fill studies where applicable.

These considerations are especially important because an automated process may operate reliably hundreds of times but still require a human intervention when an abnormal event occurs. Such exceptional interventions should therefore be anticipated and designed into the contamination-control strategy, rather than regarded simply as equipment failures.

Ultimately, the greatest microbiological benefit of robotics is not speed or labour saving. It is the ability to design human intervention out of contamination-sensitive processes. A robot placing Petri dishes inside an isolator is a relatively simple example, but it illustrates a much broader direction for pharmaceutical manufacturing: moving from controlling operator-generated contamination towards removing the opportunity for that contamination to arise in the first place.

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

From searching chemical space to designing antibiotics

                                                                                Image designed by Tim Sandle
 

Aarti Krishnan and colleagues focus further on how the rise of artificial intelligence (AI) is transforming the discovery and design of antibiotics. In their recent Viewpoint, “From code to cure: Harnessing AI for antibiotic discovery and design”, published in Science Translational Medicine, the authors examine developments involving both small-molecule antibiotics and antimicrobial peptides, while stressing that computational advances must ultimately translate into medicines that reach patients.[1] 

In the latest Pharmaceutical Microbiology news... 

Traditional antibiotic discovery faces an enormous search problem. The possible chemical space for small molecules is vast, while antimicrobial peptides introduce similarly extensive sequence possibilities. AI offers a means of exploring these spaces more systematically. Krishnan, Hanqun Cao, James J. Collins and Cesar de la Fuente-Nunez describe how AI can support the exploration of chemical and sequence spaces, the design of synthesizable antibiotics and the prioritisation of candidates according to characteristics that include safety and mechanistic diversity.[1]

This represents an important change in emphasis. AI is no longer confined to searching existing chemical libraries for promising antibacterial compounds. Generative approaches create the possibility of designing new antibiotics, potentially extending discovery beyond the chemical structures that have traditionally dominated antibacterial development.

There is already experimental evidence illustrating the potential of this approach. In separate work published in Cell, Krishnan and colleagues developed a generative deep-learning approach for de novo antibiotic design.[2] The researchers combined genetic algorithms and variational autoencoders with fragment-based and de novo design. Of 24 custom-synthesised compounds subsequently investigated, seven demonstrated selective antibacterial activity.[2]

Particularly interesting were two lead compounds demonstrating distinct modes of action against Neisseria gonorrhoeae and Staphylococcus aureus. These compounds also showed efficacy against multidrug-resistant strains and in mouse models.[2] This provides an important demonstration of the progression required in AI-assisted antibiotic discovery, moving from computational output to synthesis and then to experimental biological evaluation.

Yet computational sophistication should not be confused with successful translation. Krishnan and colleagues emphasise emerging data and reporting standards, translational pathways and regulatory hurdles as important elements in moving AI-discovered antimicrobials towards patients.[1]

Data quality and standardisation are consequently crucial. AI systems depend upon the datasets from which patterns are learned and predictions generated. For the field to mature, computational performance needs to be evaluated alongside robust experimental evidence and transparent reporting. The key question is ultimately not whether an algorithm can propose an interesting molecule, but whether the resulting compound possesses suitable antimicrobial and safety characteristics when subjected to experimental testing.

Economics presents an additional problem that AI cannot itself solve. The authors highlight the unfavourable economics surrounding antibiotics, where revenues tied to prescription volume make antibiotic development relatively unattractive to major pharmaceutical companies. As a consequence, academic laboratories and smaller biotechnology companies can carry considerable early-stage discovery risk while facing difficulties finding commercial partners prepared to advance candidates through clinical development.[1]

The significance of AI therefore lies not simply in making conventional antibiotic discovery faster. It creates opportunities to explore previously inaccessible chemical and sequence spaces and potentially to identify compounds with different structures and mechanisms. However, the real measure of success will be translation.

This makes the authors' concept of moving“from code to cure” especially pertinent. AI may generate increasingly sophisticated drug candidates, but computational discovery must be connected to experimental validation, appropriate data and reporting standards, viable development pathways and a workable regulatory environment.[1] The future of AI-enabled antibiotic discovery will therefore depend as much upon creating this translational ecosystem as upon developing increasingly powerful algorithms.

References

1. Krishnan A, Cao H, Collins JJ, de la Fuente-Nunez C. From code to cure: Harnessing AI for antibiotic discovery and design. Science Translational Medicine. 2026;18(871):eaee4629. doi:10.1126/scitranslmed.aee4629. PubMed record. [science.org], [pubmed.ncb...lm.nih.gov]

2. Krishnan A, Anahtar MN, Valeri JA, et al. A generative deep learning approach to de novo antibiotic design. Cell. 2025;188. doi:10.1016/j.cell.2025.07.033. [anahtarlab...arvard.edu]

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

FDA’s generative AI consultation closes: What should medical device manufacturers do next?

As the FDA considers how generative artificial intelligence should be regulated within medical devices, manufacturers face a growing challenge: demonstrating that systems capable of variable and evolving outputs remain safe, effective and under adequate control throughout their lifecycle.

The US Food and Drug Administration (FDA) has reached an important milestone in its consideration of generative artificial intelligence (GenAI)-enabled medical devices. The agency's public feedback period closed on 19 October 2026, following publication of its discussion paper on 18 August. The consultation, led by the FDA's Digital Health Center of Excellence, sought views from manufacturers, clinicians, researchers and other stakeholders on risk assessment, premarket evaluation and postmarket monitoring.

Importantly, the discussion paper is not a new regulation or final guidance. Rather, it provides an indication of the questions the FDA is considering as it develops an appropriate regulatory approach to GenAI-enabled technologies.

Why generative AI presents a different challenge

GenAI does not necessarily behave like conventional medical-device software. Such systems may accept open-ended inputs, undertake multiple subtasks and generate variable outputs from similar inputs. This complicates traditional approaches to verification and validation, where manufacturers seek to establish predictable performance against predefined specifications.

The FDA discussion therefore points towards risk-proportionate oversight. One concept under consideration is a two-axis approach to risk assessment, alongside competency-based approaches to premarket evaluation.

For manufacturers, the practical implication is that demonstrating satisfactory performance prior to market entry may not be enough. An AI system's behaviour in its intended clinical environment and its performance through the product lifecycle are likely to become increasingly important considerations.

This makes postmarket monitoring particularly significant. Manufacturers should consider how changes in performance can be detected, investigated and controlled, and how evidence generated after deployment feeds back into the product's risk-management process.

Compliance becomes increasingly important

These discussions also coincide with a potentially significant change in the US enforcement environment.

On 1 October, the Department of Justice issued Directive 26-12, Corporate Enforcement in the Fight Against Fraud. The directive calls for an “all-tools” approach towards specified fraud priorities and explicitly includes healthcare fraud, controlled-substance distribution and violations of the Federal Food, Drug, and Cosmetic Act among priority areas.

Legal commentators consequently suggest that FDA-regulated pharmaceutical and medical-device companies could face enhanced scrutiny. This does not mean that every regulatory deficiency will result in DOJ action, but it reinforces the value of effective compliance systems, internal controls, investigation processes and timely remediation.

What should manufacturers do now?

The FDA has not yet established final GenAI-specific requirements, so companies should avoid treating the concepts in the discussion paper as settled regulatory expectations. Nevertheless, manufacturers can prepare.

A sensible starting point is to examine existing quality and risk-management systems against the particular characteristics of GenAI. This should include clearly defining intended use, identifying safety-critical outputs and foreseeable failure modes, determining how performance will be challenged before deployment, and establishing appropriate mechanisms for detecting deterioration or unexpected behaviour afterwards.

Change control will be another critical consideration. Organisations will need to understand what aspects of an AI-enabled device may change, how those changes could affect validated performance and when additional assessment becomes necessary.

The central message is therefore familiar to pharmaceutical and medical-device quality professionals: innovation does not remove the requirement for control. As GenAI becomes increasingly sophisticated, evidence of lifecycle governance, risk management, monitoring and effective quality oversight is likely to be just as important as the sophistication of the algorithm itself.

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

How to Build Defensible Microbiological Sections in CMC Dossiers?

 

A microbiology laboratory can generate hundreds of results during development. There are bioburden counts, sterility tests, environmental monitoring, endotoxin results, microbial identification, media fills, method suitability data, and stability observations. On their own, these results are useful laboratory records. But the question is how does a regulatory reviewer relate the results to the quality of the drug product?

 

Here comes the concept of traceability. It is needed to make microbiological information defensible during submission to regulatory authorities. So, the challenge is not just to generate microbiology data. It is to turn it into a clear and traceable scientific argument for the regulatory reviewer’s evaluation.

Draft a Microbiological Risk & Control Strategy

Start by analyzing the product and processing microbiological risks. Check which can be controlled. Every pharmaceutical product doesn’t have the same risk. For example, the risk picture of a non-oral sterile liquid that could adversely affect the product may include the following:

·         Microbial proliferation in aqueous ingredients

·         Contamination introduced through equipment or water

·         Survival of objectionable microorganisms

Applying a control strategy here, especially for an aseptically manufactured injectable, is very different. It may involve sterilizing filtration, pre-filtration bioburden, environmental monitoring, container and closure preparation, aseptic process simulations, sterilization or depyrogenation processes, and finished-product sterility and endotoxin testing.

The FDA provides CGMP information that helps in differentiating the controls that are needed for non-sterile and sterile drug products. Non-sterile product manufacturers must have procedures to prevent objectionable microorganisms. Sterile products must also have written procedures that prevent microbial contamination.

Thus, the implications for reliable CMC writing are important.

Placement of Microbiology Information in the CMC Dossier

One usual misconception is that microbiology data belongs in a single section of Module 3. FDA MAPP 5040.1 provides a practical map for microbiology information in NDA and ANDA submissions. So, relevant information can appear across several CTD-Q sections. Here is the example:

·        3.2.P.2.5 — Microbiological Attributes

Information concerning microbiological attributes. It covers container closure/package integrity, preservative effectiveness, and justification where a microbial-limit specification is not included for a non-sterile product.

·        3.2.P.3.3 — Manufacturing Process and Controls

Relevant information on sterilization, depyrogenation, environmental monitoring, product bioburden, filtration, and holding periods. It is according to whatever applies to the manufacturing process.

·        3.2.P.3.5 — Process Validation and/or Evaluation

Sterilization validation, microbiological efficacy, bioburden characterization, media fills, and related validation evidence where applicable.

·        3.2.P.5.1–P.5.3—Product Specifications, Analytical Procedures, and such Procedure Validation

Information relating to attributes such as sterility, endotoxin, and microbial limits.

·        3.2.P.8.3 — Stability

It relates to the microbiological testing and testing schedule that monitors microbiological quality during storage. FDA MAPP 5040.1 identifies relevant container closure integrity/sterility, endotoxin, and microbial-limit testing.

·        3.2.A.2 — Adventitious Agent Safety Evaluation

This is important where the product or manufacturing process presents an applicable adventitious agent risk.

This means the dossier should be written as a connected story. There shouldn’t be repetition of the same microbiology information in every section.

What Makes Microbiological Data Defensible?

A defensible microbiological section is more than a collection of passing results. Four connections should be visible.

1.   What quality attribute or risk is being assessed?

A test should have a clear aim. For example, microbial enumeration may be used to assess the microbiological quality of a non-sterile product. Similarly, sterility testing becomes a part of the controls for a product required to be sterile.

2.   Is the analytical method apt for the product?

The product itself can interfere with microbiological recovery. Therefore, simply stating that a pharmacopeial method was used may not be enough. USP General Chapter <1227> explains that use of compendial microbiological procedures requires demonstration of method suitability for the product, including recovery of challenge organisms in the presence of the product. The submission should prove that the method is apt for the purpose it’s for.

WHO guides pharmaceutical microbiology laboratories, letting them address the performance and control of examination procedures and laboratory practices.

3.   What makes the acceptance norm appropriate?

Along with the specification, the CMC section should provide the scientific and regulatory reasoning that backs the chosen test and acceptance standard.

4.   Can the result be traced back to its source?

The result that’s submitted should be traceable to the batch it came from. Also, with the test method, specification, and quality records. Deviations, atypical results, or investigations that affect interpretation should be addressed properly.

Illustrative Examples of the CMC Stories

Here are some examples to explain the significance of this topic:

Example 1: Turning Sterility-Assurance Data Into a CMC Narrative

Take an aseptically filled injectable. It is manufactured using sterile filtration. A weak dossier statement might simply say that the product passed sterility testing. Also, that environmental monitoring was acceptable.

A stronger submission connects the evidence. It can describe the following:

·         Pre-filtration bioburden control

·         Sterilizing filtration process and its validation

·         Sterile preparation of containers and closures

·         Aseptic processing controls

·         Environmental monitoring

·         Media-fill qualification

·         Finished-product sterility

·         Endotoxin controls

FDA’s CTD-Q microbiology policy explicitly identifies all of this at their relevant CTD locations. The point is not to reproduce every laboratory record in the application. It is to show how the individual datasets support the sterility-assurance strategy.

Example 2: Non-Sterile Products Require a Different Chain of Proof

What if development considers water quality and microbial proliferation as huge risks? Such cases require a robust dossier. Yours should be able to connect water system, component, and manufacturing process controls. Further, it should consider preservative strategy, microbial enumeration, testing for specified microorganisms, and stability monitoring.

Officially, USP <61> is used for quantitative enumeration of aerobic mesophilic bacteria and fungi. USP <62> addresses specified microorganisms. FDA’s 2021 draft non-sterile drug guidance also stresses that manufacturers should prevent the introduction and proliferation of objectionable microorganisms. They must use appropriate microbiological controls.

So, make sure that the control strategy shows the collective working of formulation, process, facility, and testing.

Common Problems When Converting Microbiology Data Into CMC Content

Several problems can make microbiological information difficult for a reviewer to interpret. These include the following:

1.   Reporting results without explaining their purpose

A table showing microbial counts won’t be that useful when the submission lacks an explanation of which quality attribute or manufacturing risk the testing addresses.

2.   Providing specifications without sufficient rationale

The acceptance criterion should have a scientific basis that is appropriate to the product and regulatory framework.

3.   Treating compendial methods as automatically product-independent

The relevant method suitability work should be addressed where the product can interfere with microbial recovery or detection.

4.   Separating related evidence

Look into it with an aseptic product example. It may require environmental monitoring, media fills, sterilization or filtration controls, and sterility testing. Although separate, they need to come together. Then, they can support the contamination-control strategy.

5.   Same information repeating across multiple CTD sections

There can be inconsistencies due to poor cross-referencing. It may make microbiology information appear across Module 3. So, the objective should be consistency with proper cross-referencing and no duplication.

Practical Tips for the Microbiology Section

Create a simple microbiology traceability matrix before drafting.

Question	Information to capture
What is the risk?	Microbial contamination, proliferation, sterility, endotoxin, etc.
Where is the risk controlled?	Formulation, raw materials, facility, process, packaging, or testing
What is tested or monitored?	Microbial limits, sterility, endotoxin, environmental monitoring, bioburden, etc.
Which method is used?	Compendial or validated/qualified method
Is the method suitable?	Product-specific suitability or validation evidence
What is the acceptance criterion?	Defined specification or process criterion
What does the data show?	Product quality or process-control conclusion
Where does it belong in CTD?	Relevant Module 3 section

This exercise can expose gaps before submission. For example, if the specification identifies a microbiological test. However, the development section does not explain why that attribute matters. Or if the manufacturing narrative describes a microbial control without corresponding process evidence. This gap can be addressed before regulatory review.

Don’t Add More Data Without Traceability

A microbiological CMC section that is strong does not really have the largest possible volume of laboratory data. Its value comes from showing a clear chain:

Risk → Control → Method → Acceptance Basis → Result → Regulatory Conclusion

This chain is what helps reviewers understand what the microbiology laboratory found. It also explains why the result matters to the quality of the drug product. This is particularly important when microbiological information is distributed across different CTD sections. FDA's MAPP 5040.1 itself reflects this cross-sectional approach by directing microbiology reviewers to relevant information throughout CTD-Q rather than treating it as a standalone dataset.

Conclusion

Microbiology data on its own is not strong enough for CMC evidence. That’s because it emerges from controlled laboratory conditions. It becomes valuable from a regulatory perspective when there’s a connection as explained in the chain.

CMC authors should thus understand. They need not copy laboratory reports into Module 3. They should explain the scientific meaning of those results. Then, place them where they support the relevant quality argument. This clear chain is what lets a reviewer move from the microbiological result to the manufacturing control.

Ultimately, they can reach the product-quality conclusion. There won’t be any need to reconstruct the rationale themselves.

Meta Title: From Microbiology Data to CMC Dossiers | Regulatory Submission

Meta Description: Learn to turn microbiology data into a defensible CMC dossier by linking risks, controls, analytical methods, acceptance criteria, and regulatory evidence.